ES2746529T3 - Terapia génica de globina para tratar hemoglobinopatías - Google Patents

Terapia génica de globina para tratar hemoglobinopatías Download PDF

Info

Publication number: ES2746529T3
Authority: ES; Spain
Prior art keywords: region; seq; globin; set forth; nucleotide sequence
Prior art date: 2014-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES15837740T

Other languages

English (en)

Spanish (es)

Inventor

Michel Sadelain

Isabelle Riviere

Jorge Mansilla-Soto

Xiuyan Wang

George Stamatoyannopoulos

John Stamatoyannopoulos

Mingdong Liu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Washington

Memorial Sloan Kettering Cancer Center

Original Assignee

University of Washington

Memorial Sloan Kettering Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-09-04

Filing date

2015-09-04

Publication date

2020-03-06

2015-09-04 Application filed by University of Washington, Memorial Sloan Kettering Cancer Center filed Critical University of Washington

2020-03-06 Application granted granted Critical

2020-03-06 Publication of ES2746529T3 publication Critical patent/ES2746529T3/es

Status Active legal-status Critical Current

2035-09-04 Anticipated expiration legal-status Critical

Links

108060003196 globin Proteins 0.000 title claims abstract description 95
208000034737 hemoglobinopathy Diseases 0.000 title claims description 34
102000018146 globin Human genes 0.000 title description 42
238000001415 gene therapy Methods 0.000 title description 21
208000018337 inherited hemoglobinopathy Diseases 0.000 title description 7
230000014509 gene expression Effects 0.000 claims abstract description 210
125000003729 nucleotide group Chemical group 0.000 claims abstract description 192
239000002773 nucleotide Substances 0.000 claims abstract description 189
230000027455 binding Effects 0.000 claims abstract description 80
239000012212 insulator Substances 0.000 claims abstract description 57
150000007523 nucleic acids Chemical group 0.000 claims abstract description 28
102000016897 CCCTC-Binding Factor Human genes 0.000 claims abstract description 14
108010014064 CCCTC-Binding Factor Proteins 0.000 claims abstract description 14
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 252
239000013598 vector Substances 0.000 claims description 249
108090000623 proteins and genes Proteins 0.000 claims description 153
241000282414 Homo sapiens Species 0.000 claims description 102
239000003623 enhancer Substances 0.000 claims description 99
101710163270 Nuclease Proteins 0.000 claims description 86
230000000925 erythroid effect Effects 0.000 claims description 62
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 47
102000040430 polynucleotide Human genes 0.000 claims description 43
108091033319 polynucleotide Proteins 0.000 claims description 43
239000002157 polynucleotide Substances 0.000 claims description 43
208000002903 Thalassemia Diseases 0.000 claims description 42
108020004414 DNA Proteins 0.000 claims description 38
238000003776 cleavage reaction Methods 0.000 claims description 37
230000007017 scission Effects 0.000 claims description 37
108010054147 Hemoglobins Proteins 0.000 claims description 36
102000001554 Hemoglobins Human genes 0.000 claims description 36
208000007056 sickle cell anemia Diseases 0.000 claims description 35
238000013518 transcription Methods 0.000 claims description 22
230000035897 transcription Effects 0.000 claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 18
108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 18
230000002708 enhancing effect Effects 0.000 claims description 17
108010077544 Chromatin Proteins 0.000 claims description 16
210000003483 chromatin Anatomy 0.000 claims description 16
210000003743 erythrocyte Anatomy 0.000 claims description 16
230000001177 retroviral effect Effects 0.000 claims description 16
230000004568 DNA-binding Effects 0.000 claims description 15
206010020751 Hypersensitivity Diseases 0.000 claims description 15
210000000349 chromosome Anatomy 0.000 claims description 15
230000035772 mutation Effects 0.000 claims description 15
108010008532 Deoxyribonuclease I Proteins 0.000 claims description 14
102000007260 Deoxyribonuclease I Human genes 0.000 claims description 14
238000012217 deletion Methods 0.000 claims description 14
230000037430 deletion Effects 0.000 claims description 14
210000001671 embryonic stem cell Anatomy 0.000 claims description 14
210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 13
241000713666 Lentivirus Species 0.000 claims description 12
210000001519 tissue Anatomy 0.000 claims description 11
108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
206010043391 Thalassaemia beta Diseases 0.000 claims description 9
208000007502 anemia Diseases 0.000 claims description 9
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
108020005004 Guide RNA Proteins 0.000 claims description 8
238000011144 upstream manufacturing Methods 0.000 claims description 8
210000003566 hemangioblast Anatomy 0.000 claims description 7
239000002679 microRNA Substances 0.000 claims description 7
230000008488 polyadenylation Effects 0.000 claims description 7
230000007018 DNA scission Effects 0.000 claims description 6
125000000539 amino acid group Chemical group 0.000 claims description 6
208000005980 beta thalassemia Diseases 0.000 claims description 6
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
108020004705 Codon Proteins 0.000 claims description 5
208000034502 Haemoglobin C disease Diseases 0.000 claims description 5
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 5
208000012925 Hemoglobin H disease Diseases 0.000 claims description 5
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 5
241000283923 Marmota monax Species 0.000 claims description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
239000004473 Threonine Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
239000012636 effector Substances 0.000 claims description 5
208000006454 hepatitis Diseases 0.000 claims description 5
231100000283 hepatitis Toxicity 0.000 claims description 5
241000124008 Mammalia Species 0.000 claims description 4
108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 4
206010043390 Thalassaemia alpha Diseases 0.000 claims description 4
201000006288 alpha thalassemia Diseases 0.000 claims description 4
108700026220 vif Genes Proteins 0.000 claims description 4
108700011259 MicroRNAs Proteins 0.000 claims description 3
238000010459 TALEN Methods 0.000 claims description 2
108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 2
230000012010 growth Effects 0.000 claims description 2
239000005556 hormone Substances 0.000 claims description 2
229940088597 hormone Drugs 0.000 claims description 2
241000283690 Bos taurus Species 0.000 claims 1
102100021519 Hemoglobin subunit beta Human genes 0.000 abstract description 4
108091005904 Hemoglobin subunit beta Proteins 0.000 abstract description 2
230000000670 limiting effect Effects 0.000 description 128
210000001175 cerebrospinal fluid Anatomy 0.000 description 118
238000000034 method Methods 0.000 description 58
239000000203 mixture Substances 0.000 description 47
230000000694 effects Effects 0.000 description 42
235000018102 proteins Nutrition 0.000 description 32
102000004169 proteins and genes Human genes 0.000 description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
108090000765 processed proteins & peptides Proteins 0.000 description 31
102000004196 processed proteins & peptides Human genes 0.000 description 29
229920001184 polypeptide Polymers 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
102100031690 Erythroid transcription factor Human genes 0.000 description 24
102000039446 nucleic acids Human genes 0.000 description 23
108020004707 nucleic acids Proteins 0.000 description 23
210000000130 stem cell Anatomy 0.000 description 23
101710100588 Erythroid transcription factor Proteins 0.000 description 22
238000011282 treatment Methods 0.000 description 22
230000010354 integration Effects 0.000 description 20
230000006870 function Effects 0.000 description 18
239000011780 sodium chloride Substances 0.000 description 17
101001023770 Homo sapiens Transcription factor NF-E2 45 kDa subunit Proteins 0.000 description 16
102100035412 Transcription factor NF-E2 45 kDa subunit Human genes 0.000 description 16
230000001738 genotoxic effect Effects 0.000 description 16
230000006801 homologous recombination Effects 0.000 description 15
238000002744 homologous recombination Methods 0.000 description 15
230000001965 increasing effect Effects 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 15
230000001225 therapeutic effect Effects 0.000 description 15
238000010361 transduction Methods 0.000 description 15
230000026683 transduction Effects 0.000 description 15
231100000025 genetic toxicology Toxicity 0.000 description 14
238000003780 insertion Methods 0.000 description 14
230000037431 insertion Effects 0.000 description 14
230000001105 regulatory effect Effects 0.000 description 14
239000000243 solution Substances 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 13
238000013459 approach Methods 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
230000003389 potentiating effect Effects 0.000 description 13
241000699670 Mus sp. Species 0.000 description 12
230000000903 blocking effect Effects 0.000 description 12
201000010099 disease Diseases 0.000 description 12
230000005782 double-strand break Effects 0.000 description 12
239000013603 viral vector Substances 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
239000001509 sodium citrate Substances 0.000 description 11
238000012546 transfer Methods 0.000 description 11
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
229940038773 trisodium citrate Drugs 0.000 description 11
230000003612 virological effect Effects 0.000 description 11
239000011701 zinc Substances 0.000 description 11
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
230000002411 adverse Effects 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
108700019146 Transgenes Proteins 0.000 description 9
125000003275 alpha amino acid group Chemical group 0.000 description 9
150000001413 amino acids Chemical class 0.000 description 9
210000001185 bone marrow Anatomy 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
230000001404 mediated effect Effects 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
230000002103 transcriptional effect Effects 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000004888 barrier function Effects 0.000 description 8
230000008901 benefit Effects 0.000 description 8
-1 but not limited to Proteins 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
239000006185 dispersion Substances 0.000 description 8
229910001651 emery Inorganic materials 0.000 description 8
238000009472 formulation Methods 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
239000007788 liquid Substances 0.000 description 8
239000002245 particle Substances 0.000 description 8
230000005740 tumor formation Effects 0.000 description 8
238000005406 washing Methods 0.000 description 8
102000004533 Endonucleases Human genes 0.000 description 7
108010042407 Endonucleases Proteins 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
238000010322 bone marrow transplantation Methods 0.000 description 7
239000002502 liposome Substances 0.000 description 7
108020004999 messenger RNA Proteins 0.000 description 7
230000002265 prevention Effects 0.000 description 7
238000002054 transplantation Methods 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
108091033409 CRISPR Proteins 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
108010006025 bovine growth hormone Proteins 0.000 description 6
230000004069 differentiation Effects 0.000 description 6
238000002703 mutagenesis Methods 0.000 description 6
231100000350 mutagenesis Toxicity 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
208000005623 Carcinogenesis Diseases 0.000 description 5
108091026890 Coding region Proteins 0.000 description 5
102000053602 DNA Human genes 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102100027685 Hemoglobin subunit alpha Human genes 0.000 description 5
101001009091 Homo sapiens Hematopoietic lineage cell-specific protein Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
102000040945 Transcription factor Human genes 0.000 description 5
108091023040 Transcription factor Proteins 0.000 description 5
241000251539 Vertebrata <Metazoa> Species 0.000 description 5
230000004913 activation Effects 0.000 description 5
238000007792 addition Methods 0.000 description 5
230000000735 allogeneic effect Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 5
230000036952 cancer formation Effects 0.000 description 5
231100000504 carcinogenesis Toxicity 0.000 description 5
230000010437 erythropoiesis Effects 0.000 description 5
230000002068 genetic effect Effects 0.000 description 5
102000049086 human HCLS1 Human genes 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
230000007774 longterm Effects 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
230000008439 repair process Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
108700028369 Alleles Proteins 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
208000009329 Graft vs Host Disease Diseases 0.000 description 4
108091005902 Hemoglobin subunit alpha Proteins 0.000 description 4
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 4
101710185494 Zinc finger protein Proteins 0.000 description 4
102100023597 Zinc finger protein 816 Human genes 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000012937 correction Methods 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000002612 dispersion medium Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
210000004700 fetal blood Anatomy 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
238000010363 gene targeting Methods 0.000 description 4
208000024908 graft versus host disease Diseases 0.000 description 4
208000018706 hematopoietic system disease Diseases 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
230000006872 improvement Effects 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
238000001802 infusion Methods 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
108091070501 miRNA Proteins 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
241000894007 species Species 0.000 description 4
230000002463 transducing effect Effects 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108010044267 Abnormal Hemoglobins Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010068308 Hemoglobin H Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
206010052779 Transplant rejections Diseases 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000009109 curative therapy Methods 0.000 description 3
230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
230000030279 gene silencing Effects 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
208000014951 hematologic disease Diseases 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000009413 insulation Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
241000972773 Aulopiformes Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
208000019838 Blood disease Diseases 0.000 description 2
238000010354 CRISPR gene editing Methods 0.000 description 2
230000008265 DNA repair mechanism Effects 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
108091035710 E-box Proteins 0.000 description 2
241000713800 Feline immunodeficiency virus Species 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
241001663880 Gammaretrovirus Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
208000031448 Genomic Instability Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 description 2
101001009007 Homo sapiens Hemoglobin subunit alpha Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
241000714192 Human spumaretrovirus Species 0.000 description 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
108010002386 Interleukin-3 Proteins 0.000 description 2
102000000646 Interleukin-3 Human genes 0.000 description 2
206010065973 Iron Overload Diseases 0.000 description 2
206010064912 Malignant transformation Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
102000043276 Oncogene Human genes 0.000 description 2
101150084044 P gene Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
230000018199 S phase Effects 0.000 description 2
241000713311 Simian immunodeficiency virus Species 0.000 description 2
108091027967 Small hairpin RNA Proteins 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
102100031142 Transcriptional repressor protein YY1 Human genes 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
230000022131 cell cycle Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000000267 erythroid cell Anatomy 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
108700014844 flt3 ligand Proteins 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
108091008053 gene clusters Proteins 0.000 description 2
231100000024 genotoxic Toxicity 0.000 description 2
238000002746 genotoxicity assay Methods 0.000 description 2
231100000097 genotoxicity assay Toxicity 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
210000000777 hematopoietic system Anatomy 0.000 description 2
229960001330 hydroxycarbamide Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000036212 malign transformation Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000007726 management method Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
210000003593 megakaryocyte Anatomy 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000002894 multi-fate stem cell Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
210000001778 pluripotent stem cell Anatomy 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
235000019515 salmon Nutrition 0.000 description 2
239000004055 small Interfering RNA Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
241000203069 Archaea Species 0.000 description 1
241000713704 Bovine immunodeficiency virus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
101150017501 CCR5 gene Proteins 0.000 description 1
108091079001 CRISPR RNA Proteins 0.000 description 1
101150018129 CSF2 gene Proteins 0.000 description 1
101150069031 CSN2 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 1
101150074775 Csf1 gene Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
102100037241 Endoglin Human genes 0.000 description 1
241000713730 Equine infectious anemia virus Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108010044495 Fetal Hemoglobin Proteins 0.000 description 1
102100027944 Flavin reductase (NADPH) Human genes 0.000 description 1
230000010337 G2 phase Effects 0.000 description 1
101150106478 GPS1 gene Proteins 0.000 description 1
241000713813 Gibbon ape leukemia virus Species 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101150116759 HBA2 gene Proteins 0.000 description 1
101150052743 Hba1 gene Proteins 0.000 description 1
208000009336 Hemoglobin SC Disease Diseases 0.000 description 1
108010081925 Hemoglobin Subunits Proteins 0.000 description 1
108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
108010034791 Heterochromatin Proteins 0.000 description 1
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
101000618535 Homo sapiens DNA repair protein complementing XP-C cells Proteins 0.000 description 1
101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
101100230565 Homo sapiens HBB gene Proteins 0.000 description 1
101000598921 Homo sapiens Orexin Proteins 0.000 description 1
101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 1
101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
101001123245 Homo sapiens Protoporphyrinogen oxidase Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000891113 Homo sapiens T-cell acute lymphocytic leukemia protein 1 Proteins 0.000 description 1
101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
241001505307 Jembrana disease virus Species 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
108020005196 Mitochondrial DNA Proteins 0.000 description 1
108010086093 Mung Bean Nuclease Proteins 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108050002069 Olfactory receptors Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010031264 Osteonecrosis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 1
102100040120 Prominin-1 Human genes 0.000 description 1
102100029028 Protoporphyrinogen oxidase Human genes 0.000 description 1
108060006897 RAG1 Proteins 0.000 description 1
101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101001025539 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Homothallic switching endonuclease Proteins 0.000 description 1
101000702553 Schistosoma mansoni Antigen Sm21.7 Proteins 0.000 description 1
101000714192 Schistosoma mansoni Tegument antigen Proteins 0.000 description 1
108010016797 Sickle Hemoglobin Proteins 0.000 description 1
108010019965 Spectrin Proteins 0.000 description 1
102000005890 Spectrin Human genes 0.000 description 1
241000713675 Spumavirus Species 0.000 description 1
102000015215 Stem Cell Factor Human genes 0.000 description 1
108010039445 Stem Cell Factor Proteins 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
102100040365 T-cell acute lymphocytic leukemia protein 1 Human genes 0.000 description 1
102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
101710122472 Transcriptional repressor protein YY1 Proteins 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
102000008579 Transposases Human genes 0.000 description 1
108010020764 Transposases Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
238000010317 ablation therapy Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
210000004504 adult stem cell Anatomy 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
244000000005 bacterial plant pathogen Species 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
208000022809 beta-thalassemia intermedia Diseases 0.000 description 1
208000022806 beta-thalassemia major Diseases 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000007073 chemical hydrolysis Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
208000035623 congenital anemia Diseases 0.000 description 1
238000010276 construction Methods 0.000 description 1
101150055601 cops2 gene Proteins 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
210000003981 ectoderm Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 1
210000001900 endoderm Anatomy 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000005021 gait Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
210000001654 germ layer Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000003278 haem Chemical class 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
210000004458 heterochromatin Anatomy 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
102000046965 human XPC Human genes 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
LFEUVBZXUFMACD-UHFFFAOYSA-H lead(2+);trioxido(oxo)-$l^{5}-arsane Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O LFEUVBZXUFMACD-UHFFFAOYSA-H 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
210000003716 mesoderm Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000037230 mobility Effects 0.000 description 1
238000002715 modification method Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000010413 mother solution Substances 0.000 description 1
210000000066 myeloid cell Anatomy 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
210000001178 neural stem cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000005868 ontogenesis Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000004991 placental stem cell Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001343 polytetrafluoroethylene Polymers 0.000 description 1
239000004810 polytetrafluoroethylene Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000004853 protein function Effects 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
230000008263 repair mechanism Effects 0.000 description 1
230000008672 reprogramming Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000000717 tumor promoter Substances 0.000 description 1
238000003160 two-hybrid assay Methods 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
238000009777 vacuum freeze-drying Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000001325 yolk sac Anatomy 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

ES15837740T 2014-09-04 2015-09-04 Terapia génica de globina para tratar hemoglobinopatías Active ES2746529T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462045997P	2014-09-04	2014-09-04
PCT/US2015/048698 WO2016037138A1 (fr)	2014-09-04	2015-09-04	Thérapie génique globale destinée à traiter les hémoglobinopathies

Publications (1)

Publication Number	Publication Date
ES2746529T3 true ES2746529T3 (es)	2020-03-06

Family

ID=55440425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES15837740T Active ES2746529T3 (es)	2014-09-04	2015-09-04	Terapia génica de globina para tratar hemoglobinopatías

Country Status (11)

Country	Link
US (2)	US11717579B2 (fr)
EP (3)	EP3620521B1 (fr)
JP (3)	JP6710680B2 (fr)
KR (2)	KR102500531B1 (fr)
CN (3)	CN114457076A (fr)
AU (2)	AU2015311681B2 (fr)
BR (1)	BR112017004349A2 (fr)
CA (1)	CA2960209C (fr)
ES (1)	ES2746529T3 (fr)
MX (1)	MX382337B (fr)
WO (1)	WO2016037138A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015229227B2 (en)	2014-03-14	2021-03-18	University Of Washington	Genomic insulator elements and uses thereof
AU2017370640A1 (en)	2016-12-05	2019-07-18	The Regents Of The University Of California	Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathies
TW201839136A (zh)	2017-02-06	2018-11-01	瑞士商諾華公司	治療血色素異常症之組合物及方法
JP7228523B2 (ja) *	2017-03-29	2023-02-24	ブルーバードバイオ，インコーポレイテッド	ヘモグロビン異常症を治療するためのベクターおよび組成物
US12139720B2 (en)	2017-06-02	2024-11-12	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Recombinant lentiviral vector for stem cell- based gene therapy of sickle cell disorder
MX2020004092A (es)	2017-10-18	2021-01-08		Composiciones de virus adenoasociados para restaurar la funcion del gen hbb y metodos de uso de estas.
EP3720509A4 (fr) *	2017-12-06	2021-12-08	Memorial Sloan-Kettering Cancer Center	Thérapie génique avec un gène de globine pour le traitement des hémoglobinopathies
EP3788070A4 (fr) *	2018-04-30	2022-03-09	The Children's Hospital Of Philadelphia	Compositions et procédés de production d'hémoglobine
US12241079B2 (en)	2018-09-14	2025-03-04	The Children's Hospital Of Philadelphia	Compositions and methods for hemoglobin production
EP3886869A4 (fr) *	2018-11-28	2022-07-06	Forty Seven, Inc.	Csph génétiquement modifiées résistantes au traitement ablatif
US20220136007A1 (en) *	2019-02-14	2022-05-05	The Regents Of The University Of California	Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathies
US20220170045A1 (en) *	2019-02-28	2022-06-02	The Regents Of The University Of California	Augmentations to lentiviral vectors (cclc-mgata/ank-core lcr-beta-as3-fb) to increase expression
CN110042124A (zh) *	2019-04-25	2019-07-23	国家卫生健康委科学技术研究所	基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用
CN109999053B (zh) *	2019-04-26	2021-03-23	周德旺	曲氟尿苷或曲氟尿苷替匹嘧啶组合物的医药用途
CN110106203B (zh) *	2019-05-24	2023-08-11	中国医学科学院血液病医院（血液学研究所）	一种新型hbb过表达载体及其设计方法和应用
CN110699381A (zh) *	2019-09-17	2020-01-17	合肥瑞灵生物科技有限公司	地中海贫血病基因治疗载体构建方法及其用途
US20220411822A1 (en) *	2020-01-22	2022-12-29	Altius Institute For Biomedical Sciences	Novel Erythroid Specific Enhancers and Uses Thereof
JP7031690B2 (ja) *	2020-01-27	2022-03-08	株式会社三洋物産	遊技機
CN115768901A (zh) *	2020-04-13	2023-03-07	弗莱德哈钦森癌症中心	腺病毒的大负载整合
US20240350664A1 (en) *	2020-11-23	2024-10-24	Intas Pharmaceuticals Ltd.	Gene therapy based administration of lentivirus vector for treating hemoglobinopathies
JP2024506645A (ja) *	2021-02-11	2024-02-14	コーニンクレッカネザーランドアカデミーヴァンウェテンシャッペン	転写調節遺伝子の編集による疾患の治癒
US20240209336A1 (en) *	2021-03-31	2024-06-27	Sigilon Therapeutics, Inc.	Genetically modified human cell lines and uses thereof
CN113106098B (zh) *	2021-04-21	2022-04-01	贵州医科大学	一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用
CN113564248A (zh) *	2021-09-26	2021-10-29	北京贝瑞和康生物技术有限公司	同时检测hba1/2、hbb和hbd基因位点多种突变的方法和试剂盒
CN114457119B (zh) *	2022-04-11	2022-08-12	中吉智药(南京)生物技术有限公司	慢病毒载体在制备治疗β-地中海贫血药物中的应用
EP4536862A1 (fr) *	2022-06-09	2025-04-16	Wisconsin Alumni Research Foundation	Génération de vecteurs de thérapie génique aav recombinés de nouvelle génération adoptant une conformation 3d
WO2024186677A2 (fr) *	2023-03-03	2024-09-12	Altius Institute For Biomedical Sciences	Protéines de liaison à l'adn pour réguler l'expression de l'hémoglobine
CN116271106B (zh) *	2023-05-24	2023-08-11	中吉智药(南京)生物技术有限公司	慢病毒载体LentilAlpha在制备治疗α-地中海贫血药物中的应用
CN119907866A (zh) *	2023-06-15	2025-04-29	天津华大医学检验所有限公司	检测11种地中海贫血拷贝数变异的引物组和试剂盒
WO2025151744A1 (fr)	2024-01-10	2025-07-17	University Of Tennessee Research Foundation	Globine améliorée et autres vecteurs lentiviraux destinés à une thérapie génique
CN118006803B (zh) *	2024-03-21	2025-02-14	西北农林科技大学	一种与绵羊高海拔适应相关的分子标记及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873192A (en)	1987-02-17	1989-10-10	The United States Of America As Represented By The Department Of Health And Human Services	Process for site specific mutagenesis without phenotypic selection
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5725871A (en)	1989-08-18	1998-03-10	Danbiosyst Uk Limited	Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en)	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5756353A (en)	1991-12-17	1998-05-26	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es)	1992-05-18	1997-10-16	Minnesota Mining & Mfg	Dispositivo de suministro de farmaco a traves de las mucosas.
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
IL178921A0 (en)	1998-12-24	2007-03-08	Yeda Res & Dev	Caspase-8 interacting proteins
WO2003002155A1 (fr) *	2001-06-29	2003-01-09	Sloan Kettering Institute For Cancer Research	Vecteur codant pour le gene-globine humain et utilisation de celui-ci dans le traitement d'hemoglobinopathies
AU2003245488A1 (en) *	2002-06-13	2003-12-31	Regulome Corporation	Functional sites
US20080069805A1 (en) *	2005-05-18	2008-03-20	Williams Bruce M	Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia
WO2008101216A2 (fr)	2007-02-15	2008-08-21	The Govt. Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services	Séquences isolantes satellites gamma et leurs utilisations dans la prévention du silençage de gènes
US8790345B2 (en)	2007-08-21	2014-07-29	Zimmer, Inc.	Titanium alloy with oxidized zirconium for a prosthetic implant
US20090156534A1 (en) *	2007-09-13	2009-06-18	Memorial Sloan-Kettering Cancer Center	Globin lentiviral vectors for treatment of disease
US20110294873A1 (en) *	2008-10-23	2011-12-01	Université de Lausanne	Gene Transfer Vectors Comprising At Least One Isolated DNA Molecule Having Insulator Or Boundary Properties And Methods To Identify The Same
EP2414524B1 (fr)	2009-04-03	2017-08-23	Centre National De La Recherche Scientifique	Vecteurs de transfert de gènes comprenant des isolants génétiques et procédés d'identification d'isolants génétiques
US8586526B2 (en)	2010-05-17	2013-11-19	Sangamo Biosciences, Inc.	DNA-binding proteins and uses thereof
WO2014019860A2 (fr)	2012-08-03	2014-02-06	Abb Technology Ag	Limitation de surcharge en fonctionnement de puissance de crête
US8823480B2 (en)	2012-08-10	2014-09-02	Tyco Electronics Corporation	Planar electronic device
US20150216903A1 (en) *	2012-08-10	2015-08-06	Bluebird Bio, Inc.	Compounds for improved viral transduction
JP2015529466A (ja) *	2012-09-14	2015-10-08	ザリージェンツオブザユニバーシティオブカリフォルニア	鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
JP6509884B2 (ja) *	2014-01-30	2019-05-08	チルドレンズホスピタルメディカルセンター	鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン
AU2015229227B2 (en) *	2014-03-14	2021-03-18	University Of Washington	Genomic insulator elements and uses thereof

2015
- 2015-09-04 EP EP19185730.9A patent/EP3620521B1/fr active Active
- 2015-09-04 KR KR1020177008935A patent/KR102500531B1/ko active Active
- 2015-09-04 CN CN202210122741.1A patent/CN114457076A/zh active Pending
- 2015-09-04 JP JP2017512966A patent/JP6710680B2/ja active Active
- 2015-09-04 KR KR1020237005064A patent/KR20230030002A/ko not_active Ceased
- 2015-09-04 CN CN201580060160.8A patent/CN107208093B/zh active Active
- 2015-09-04 CN CN202210122739.4A patent/CN114480393A/zh active Pending
- 2015-09-04 MX MX2017002900A patent/MX382337B/es unknown
- 2015-09-04 ES ES15837740T patent/ES2746529T3/es active Active
- 2015-09-04 WO PCT/US2015/048698 patent/WO2016037138A1/fr not_active Ceased
- 2015-09-04 CA CA2960209A patent/CA2960209C/fr active Active
- 2015-09-04 EP EP24178429.7A patent/EP4438115A3/fr not_active Withdrawn
- 2015-09-04 BR BR112017004349A patent/BR112017004349A2/pt not_active Application Discontinuation
- 2015-09-04 EP EP15837740.8A patent/EP3189143B1/fr active Active
- 2015-09-04 AU AU2015311681A patent/AU2015311681B2/en active Active
2017
- 2017-03-03 US US15/449,416 patent/US11717579B2/en active Active
2020
- 2020-03-03 JP JP2020035649A patent/JP7158427B2/ja active Active
2021
- 2021-12-21 AU AU2021290257A patent/AU2021290257B2/en not_active Expired - Fee Related
2022
- 2022-06-01 JP JP2022089526A patent/JP2022107736A/ja active Pending
2023
- 2023-01-26 US US18/160,083 patent/US20240066148A1/en active Pending

Also Published As

Publication number	Publication date
AU2015311681A1 (en)	2017-04-13
AU2015311681B2 (en)	2021-09-23
AU2015311681A8 (en)	2019-08-08
KR20230030002A (ko)	2023-03-03
US11717579B2 (en)	2023-08-08
AU2021290257A1 (en)	2022-01-27
JP2022107736A (ja)	2022-07-22
EP4438115A2 (fr)	2024-10-02
JP6710680B2 (ja)	2020-06-17
KR102500531B1 (ko)	2023-02-17
EP3189143A1 (fr)	2017-07-12
MX382337B (es)	2025-03-13
CN107208093A (zh)	2017-09-26
WO2016037138A8 (fr)	2017-03-16
EP3620521B1 (fr)	2024-05-29
EP4438115A3 (fr)	2025-01-08
CA2960209A1 (fr)	2016-03-10
EP3620521A1 (fr)	2020-03-11
EP3189143B1 (fr)	2019-08-07
BR112017004349A2 (pt)	2017-12-05
JP2020079327A (ja)	2020-05-28
CN114480393A (zh)	2022-05-13
JP2017532023A (ja)	2017-11-02
JP7158427B2 (ja)	2022-10-21
MX2017002900A (es)	2017-10-24
AU2021290257B2 (en)	2025-08-21
US20170173185A1 (en)	2017-06-22
CA2960209C (fr)	2023-08-29
CN107208093B (zh)	2022-03-01
EP3189143A4 (fr)	2018-03-21
WO2016037138A1 (fr)	2016-03-10
KR20170044752A (ko)	2017-04-25
US20240066148A1 (en)	2024-02-29
CN114457076A (zh)	2022-05-10

Publication	Publication Date	Title
ES2746529T3 (es)	2020-03-06	Terapia génica de globina para tratar hemoglobinopatías
US12606848B2 (en)	2026-04-21	Globin gene therapy for treating hemoglobinopathies
ES2942309T3 (es)	2023-05-31	Materiales y métodos para el tratamiento de hemoglobinopatías
CN118581154A (zh)	2024-09-03	用于遗传障碍的基因疗法的基因组编辑手段和结合病毒载体的基因疗法
CN104284669A (zh)	2015-01-14	治疗血红蛋白病的组合物和方法
Bueren et al.	2020	Advances in the gene therapy of monogenic blood cell diseases
JP7522782B2 (ja)	2024-07-25	Ｐｋｌｒの遺伝子発現増強のための組成物および方法
Cottle et al.	2016	Treating hemoglobinopathies using gene-correction approaches: promises and challenges
US20220056484A1 (en)	2022-02-24	Selection by means of artificial transactivators
Buffa et al.	2023	Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders
Drakopoulou et al.	2013	Towards more successful gene therapy clinical trials for β-thalassemia
Gutiérrez-Guerrero	2018	Gene editing as an alternative to retroviral vectors for Wiskott-Aldrich syndrome gene therapy
Firrito	2015	Targeted Gene Correction and Reprogramming of SCID-X1 Fibroblasts to Rescue IL2RG Expression in iPSC-derived Hematopoietic Cells
Gorter	0	Retroviral vectors and transposons for stable gene therapy and manufacturing vaccines